SNSE Sensei Biotherapeutics, Inc.

Price Chart

Executive Summary

Sensei Biotherapeutics filed an S-3/A to register up to 24,868,028 shares of common stock for resale by selling stockholders, all shares issued in the Faeth acquisition and a concurrent private placement. The filing is a procedural step required by the registration rights agreement — no company capital raise is involved, but it unlocks the potential for massive overhang to hit the market after stockholder approvals.

Actionable Insight

Key Facts

• S-3/A registers up to 24,868,028 shares for resale by stockholders: 10,425,531 Merger Conversion Shares, 14,440,395 Private Placement Conversion Shares, and 2,102 Warrant Conversion Shares
• Company received no proceeds from this resale registration — the ~$200M PIPE already closed February 20, 2026 at ~$13.85 per as-converted share
• Shares can only be resold after stockholder approval of the Conversion Proposal and Authorized Share increase (from 12.5M to 300M authorized shares) at the Annual Meeting
• Current shares outstanding as of March 31, 2026 were only 1,340,333 — the registered resale shares represent ~18.6x the current share count
• On May 31, 2026, the stock closed at $21.14, representing a ~53% premium to the PIPE price of ~$13.85
• Lock-up agreements exist for certain holders but the registration covers a broad set of PIPE investors and Faeth stockholders
• Cross-filing 10-Q (May 15, 2026) confirms the company is a clinical-stage biotech with no approved products and significant ongoing cash burn

Financial Impact

Potential dilution of up to 24.9M shares (existing public float of ~1.3M shares would increase ~19x post-conversion; valuation impact depends on pace and volume of selling, but overhang is material)

Risk Factors

• Extreme dilution from conversion of Series B Preferred into 24.9M common shares — a ~19x increase in the public float
• PIPE investors hold shares at ~$13.85 cost basis, currently at a 53% gain — strong incentive to sell post-conversion
• No underwritten offering — selling stockholders control timing and volume, creating unpredictable selling pressure
• Clinical-stage pipeline (PIKTOR Phase 2 endometrial cancer data expected YE 2026) means binary catalyst risk before overhang clears
• Stockholder vote required for conversion — any delay or failure is positive for the stock but would strain Nasdaq listing status

Market Snapshot

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

US Market Status